This is the authors' abstract. We don't add key points for this paper.
Metastasis is the leading cause of death in triple-negative breast cancer (TNBC), yet how tumor cells evade immune recognition during dissemination remain unclear. Here, we show that de novo lipogenesis drives metastatic immune evasion through FASN-mediated palmitoylation of EGFR. This modification establishes a lipid-dependent membrane signaling scaffold that sustains PI3K-AKT-mTOR signaling independently of MAPK compensation, thereby suppressing MHC-I antigen presentation through post-translational regulation. As a result, metastatic-competent cells escape CD8+ T cell surveillance and colonize distant organs. Genetic or pharmacologic inhibition of fatty acid synthase (FASN), or expression of palmitoylation-deficient EGFR mutants restores MHC-I surface expression, unleashes robust CD8⁺ T cell activation, and markedly impairs lung metastasis without affecting primary tumor growth. This lipid-dependent EGFR-PI3K-mTOR axis operates independently of MAPK signaling and is not rescued by exogenous lipids, revealing a non-redundant metabolic dependency. Our results identify FASN-driven EGFR palmitoylation as a tumor-intrinsic immunometabolic checkpoint that couples lipid metabolism to antigen-presentation and metastatic competence. Targeting this pathway with clinically advancing FASN inhibitors offers a promising strategy to suppress metastasis by restoring anti-tumor immunity in TNBC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: